PubMed Health⌕ Search

Biomedical subjects

Neil R MacIntyre

Publications and source records attributed to Neil R MacIntyre.

6 recordsLinked to original sources

Pulmonary function testing: coding and billing issues.

Clinicians who conduct pulmonary function tests should understand the principles and rules of the coding and billing system for pulmonary function testing. Certain billing codes will not be paid by most insurance payers. To ensure that your pulmonary function tests are appropriately coded, billed, and paid: (1) obtain a Current Procedural Terminology (CPT) coding book and an International Classification of Diseases 9th Revision (ICD-9) diagnosis book, and understand how they are used in setting coding and billing strategies, (2) know the people in your facility who do the billing and work with them to produce an appropriate coding and billing strategy, (3) make sure the physicians are involved in developing and implementing your coding and billing strategy, and (4) assure that your laboratory is set up properly to follows the Medicare rules for participation, that you have the appropriate testing supervision, that the appropriate administrative structure is in place to assure compliance with all regulations, and that you meet American Thoracic Society testing standards.

Fees and Charges↗

Intrabreath diffusing capacity of the lung in healthy individuals at rest and during exercise.

BACKGROUND: Traditional approaches to measuring the diffusing capacity of the lung for carbon monoxide (DLCO) treat the lung as a single, well-mixed compartment and produce a single value for DLCO to represent an average diffusing capacity of the lung (DL). Because DL distribution in the lung is inhomogeneous, and changes in the DL in diseased lungs may be regional, measuring regional DL, especially during exercise, may be more sensitive in detecting pulmonary vascular diseases. OBJECTIVES: To characterize regional changes in DL in healthy individuals from rest to exercise, and to provide normal references for future studies in pulmonary vascular disorders. METHODS: We reanalyzed DLCO and phase III CH(4) slopes that were obtained during a slow, single exhalation at rest and during exercise in our extended database of 105 healthy individuals. DLCO profiles between 20% and 80% of exhaled vital capacity (VC) (ie, the intrabreath DLCO) were analyzed by calculating the average DLCO measured at midlung volume (ie, 30 to 45% of exhaled VC [DLCOMLV]) and by fitting the whole curve with a third-order polynomial equation. RESULTS: DLCO decreased nonlinearly by approximately 30%, from 20 to 80% of exhaled VC at rest. DLCO during exercise was greater than that at rest, and the increase was similar at all lung volumes. The CH(4) slopes at rest and during exercise were similar. Prediction equations based on regressions on age, sex, and height were computed for resting and exercise DLCOMLV and the phase III CH(4) slope (an index of ventilation distribution). CONCLUSIONS: Capillary recruitment/dilation during exercise in healthy individuals is a uniform process throughout the lungs. Our analyses provide a database for a noninvasive method that can incorporate exercise to evaluate the volume-dependent distribution of DLCO in lung diseases.

Adult↗

Setting the frequency-tidal volume pattern.

Alveolar (and thus arterial) P(O2) and P(CO2) clearly depend on minute ventilation. However, we need to balance gas exchange goals against the risk of overstretching, especially of the healthier regions of the lung. The plateau pressure is probably the best easily-obtained marker of the risk of stretch in the lung, and a commonly quoted threshold is 30--35 cm H(2)O, the normal maximum transalveolar pressure at total lung capacity. In establishing the proper balance of stretch versus gas exchange, we need to address what levels of pH and P(aO2) we consider acceptable. There are no good data to guide us on the lowest tolerable pH, but 7.2 is commonly quoted in the literature, and 7.15 was the lower limit of acceptability in the ARDS (acute respiratory distress syndrome) Network trial. P(O2) levels as low as 55 mm Hg may be well tolerated, provided there is reasonable oxygen delivery. In distributing the desired minute volume between respiratory frequency and tidal volume (V(T)), a V(T) of 6 mL/kg ideal body weight has been shown to improve ARDS outcome, compared to 12 mL/kg. Thus, 6 mL/kg should be the "start point." Adjustments upward could be considered the plateau pressure is acceptable, in order to improve gas exchange or comfort. Conversely, downward adjustments should be considered if the plateau pressure is high and the gas exchange is acceptable. Frequency is adjusted for the desired minute ventilation. It must be recognized, however, that as frequency (and minute ventilation) increases, the risk of air trapping and intrinsic positive end-expiratory pressure (PEEP) increases. Just like applied PEEP, intrinsic PEEP increases the baseline pressure and stretch upon which the V(T) is delivered. The end-inspiratory stretch increases accordingly. The shape and duration of the flow pattern may affect gas mixing, recruitment, cardiac function, intrinsic PEEP buildup, and patient comfort. It is also conceivable that certain flow patterns can produce an acceleration injury. Although small clinical trials using physiologic end points espouse certain flow patterns, there are no good outcome data at present supporting any particular approach. Some authors suggest that high-frequency ventilation (HFV) might be considered an "ultimate" lung-protective strategy. HFV creates considerable intrinsic PEEP, which, when coupled with sustained inflation maneuvers, can provide substantial alveolar recruitment. In addition, the small V(T) of HFV prevents excessive end-inspiratory distention. Although considerable clinical data support the use of HFV in pediatric patients at risk for ventilator-induced lung injury, there are few data from adults. Whether HFV will prove valuable in well-designed open lung strategies in the adult population still has to be determined.

Carbon Dioxide↗

Aerosol delivery through an artificial airway.

For both lung and systemic diseases, aerosol delivery of drugs into the lungs can often offer substantial advantages over other routes of administration. In the intensive care unit, however, the artificial airway can be a substantial barrier to aerosol delivery, so clinicians must pay careful attention to the ventilator pattern, the delivery gas humidity/density, the device characteristics, and the circuit/tube properties. When those are optimized, aerosol delivery from a nebulizer or metered-dose inhaler and through an endotracheal tube can begin to approach that seen in a nonintubated patient. Novel approaches, such as generating the aerosol within the airway, offer the opportunity to greatly increase deposition efficiency and focal drug targeting in intubated patients.

Aerosols↗